New research from life sciences industry software provider Veeva Systems (NYSE: VEEV) finds that all respondents surveyed report the need to improve information exchange among study partners.
On average, they utilize at least three methods to share trial data and documents among sponsors, CROs, and sites, with email as the primary tool.
Majorities say the move to streamline information exchange is driven by the need to reduce manual processes, improve collaboration, and increase visibility and oversight during trials.
Nearly all sponsors and CROs say they also need to unify clinical applications for greater visibility and easier collaboration.
Many of the challenges in managing trials stem from siloed processes and systems that prevent a complete view of study progress and slow trial execution. Integration and reporting are the top two issues cited both are the direct result of clinical system silos.
Study start-up is one of the clinical areas with the most potential to improve trial efficiency and speed. All respondents report significant challenges with study start-up, likely due to the heavy reliance on manual processes since most use spreadsheets to manage this area.
Sponsors and CROs are increasingly adopting purpose-built study start-up applications to speed cycle times. Nearly one-quarter of respondents are now using newer, purpose-built study start-up applications.
Findings show that the majority cite faster study start-up times as the primary driver to improve study start-up processes.
Half of respondents say easier collaboration during study start-up is also an area of improvement, highlighting the importance of collaboration in driving clinical trial efficiency and speed.
Over the past several years, sponsors and CROs have steadily adopted function-specific applications to improve study execution.
The industry is modernizing its processes and systems in major clinical areas such as eTMF and are seeing positive impact.
Sponsors and CROs, however, report challenges in other areas such as CTMS because of the prevalence of legacy systems.
Nearly all respondents say they need to improve the use of CTMS in clinical operations. For most, better analytics and reporting and increased visibility are among the primary reasons.
Roughly half of sponsors and CROs also say easier collaboration is a top driver, underscoring the importance of streamlining communication and information sharing during execution.
The number of respondents using purpose-built eTMF applications has tripled since 2014.
At the same time, the use of general-purpose methods to manage TMF processes has decreased, indicating the continued move from TMFs that act as static repositories to store and archive documents upon completion to modern purpose-built eTMF applications that enable more 'active' trial management.
Those using purpose-built eTMF solutions report improved ability to maintain a constant state of inspection-readiness and visibility into TMF status.
The Veeva 2019 Unified Clinical Operations Survey examines the life sciences industry's progress toward a unified clinical environment by gathering the experiences and opinions of 461 clinical operations professionals from around the globe.
The annual research examines the drivers, barriers, and benefits of a unified clinical operating model and tracks the industry's progress in its move to unify clinical systems and processes and align stakeholders throughout study execution.
Veeva Systems is in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 750 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs.
Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients